Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo

Table 3 Predictors of mortality among EVD cases included in the analyses

	n	Duration *	Event**	Death Incidence /1000 Patient-Day	Hazard Ratio *
	n	Duration *	Event**	Death Incidence /1000 Patient-Day	Crude	p	Adjusted	p
Age							1.01	0.179
Time from onset of illness to admission (days)							1.05	< 0.001
Gender
Female	457	4888	198	40.5	1		1
Male	327	3742	121	32.3	0.82	0.116	0.85	0.209
Profession
Others	704	7685	298	38.8	1		1
Health professionals	69	812	19	23.4	0.63	0.060	0.88	0.657
Butcher/religious leader	11	133	2	15.0	0.41	0.205	0.46	0.276
Vaccine status
Not received	391	4317	170	39.4	1		1
Received	150	1888	40	21.2	0.55	0.001	0.57	0.003
Unknown	185	2072	77	37.2	0.94	0.694	0.99	0.997
Harm
No EVD-specific treatment	55	98	49	500.0	1		1
MAb114	215	2566	64	24.9	0.20	< 0.001	0.27	< 0.001
REGN-EB3	243	2878	78	27.1	0.21	< 0.001	0.26	< 0.001
Remdesivir	167	1915	77	40.2	0.31	< 0.001	0.38	0.005
ZMapp	104	1173	51	43.5	0.37	< 0.001	0.47	0.032
Total	784	8630	319	37.0

*: duration in days **: death
The survival benefits reported in the MAb114 and REGN-EB3 groups, relative to patients who received «No EVD-specific treatment», are verified in Figs. 2 and 3 below

ISSN: 1743-422X